Taken together, our study underscores the critical role of mi RNA128a as an epigenetic regulator of FADD expression in RA pathogenesis and further suggests that TMZ holds promise as an antirheumatoid candidate, offering improved therapeutic results with a reduced risk of adverse effects. Here, FADD is linked to rheumatoid arthritis.